Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.56 |
| ▸ | PREP | P48147 | 2/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12949889 | 1.00 | DPP4 (0.56) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL10421372 | 1.00 | DPP4 (0.56) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL23314867 | 0.84 | DPP4 (0.51) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL14609170 | 0.81 | DPP4 (0.41) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL4589694 | 0.81 | POLB (0.37) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL12324861 | 0.81 | DPP4 (0.41) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL14273591 | 0.81 | DPP4 (0.41) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL18519489 | 0.79 | DPP4 (0.36) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL6389769 | 0.78 | ACE (0.41) | POLBL3MBTL1ACE | |
| SCHEMBL20038765 | 0.78 | EPHX1 (0.38) | DPP4PREPFAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183292-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183292-A1 | IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | DPP4 1694/4885DPP8 1502/4885PREP 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.